Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?

Different therapy strategies for coronary disease in conventionally untreatable patients have been developed, among them transmyocardial laser revascularization (TMLR) and the application of growth factors. The objective of our study was to determine whether a combined therapy of TMLR with a vascula...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cardio-thoracic surgery 2003-01, Vol.23 (1), p.74-80
Hauptverfasser: Heilmann, Claudia A U, Attmann, Tim, von Samson, Patrick, Göbel, Heike, Marmé, Dieter, Beyersdorf, Friedhelm, Lutter, Georg
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 80
container_issue 1
container_start_page 74
container_title European journal of cardio-thoracic surgery
container_volume 23
creator Heilmann, Claudia A U
Attmann, Tim
von Samson, Patrick
Göbel, Heike
Marmé, Dieter
Beyersdorf, Friedhelm
Lutter, Georg
description Different therapy strategies for coronary disease in conventionally untreatable patients have been developed, among them transmyocardial laser revascularization (TMLR) and the application of growth factors. The objective of our study was to determine whether a combined therapy of TMLR with a vascular endothelial growth factor(121) (VEGF(121)) plasmid is able to stimulate the development of sufficient collateral circulation and hereby to preserve cardiac function. A severe stenosis of the left anterior descending artery was created in healthy pigs. After 1 week, perfusion and regional contractility were assessed at baseline. Afterwards, the ischemic area was treated with TMLR (n=8), intramyocardial injection of naked plasmid DNA encoding VEGF(121) (n=7), or both (n=7). Control animals were left untreated (n=8). After 3 months, the animals were re-examined and underwent immunohistological analysis. The number of capillaries increased only after injection of VEGF(121) plasmid alone compared to untreated ischemia and to the other therapy groups, whereas the number of arterioles was higher following TMLR treatment alone or in combination with VEGF(121) than it was in the case in untreated ischemic animals. However, only combined VEGF(121)+TLMR therapy resulted in an improvement in regional myocardial blood flow in comparison with 1 week ischemia, indicating the efficient development of collateral circulation. In contrast, better regional contractility compared to the 1-week baseline, as well as restoration of the pre-ischemic values, were achieved by both VEGF(121) and combined VEGF(121)+TLMR therapies. This study of chronic myocardial ischemia with a porcine model indicates a synergistic action of TMLR and VEGF(121) gene therapy. Combined treatment alone achieved an increase of regional myocardial perfusion, which accompanied arteriogenesis and corresponded with the restoration of regional function.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72885836</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72885836</sourcerecordid><originalsourceid>FETCH-LOGICAL-p548-162a411b2006335fe6698131924ad85afd247ba8798a505c113aeec295acaf83</originalsourceid><addsrcrecordid>eNpNkM9Kw0AQxnNQbK2-guxJ9BDY3fzbnERKrULBg8VrmOxOmpVNNu4mlvhYPqEptuBpBr7fzHzfnAVzRhkNszyms-DS-w9KaRrx7CKYMR7nUULFPPjZOmh9M1oJTmkwxIBHRxx-gZeDAae_ode2JdI2pW5Rkb3ua3JSCbbK9jWaw-jO2f2kVSB76wjjjNy9r9ZPU3NPdtgimUAH3UiqSZa1s62W5N9p7WWNjYYwVPbAEqwqlL2f3IAxIwGlyNA9XAXnFRiP18e6CN6eVtvlc7h5Xb8sHzdhl8QiZCmHmLGSH0JHSYVpmgsWsZzHoEQCleJxVoLIcgEJTSRjESBKnicgoRLRIrj929o5-zmg74tm8ofGQIt28EXGhUhElE7gzREcygZV0TndgBuL04-jX3Ytebo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72885836</pqid></control><display><type>article</type><title>Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Heilmann, Claudia A U ; Attmann, Tim ; von Samson, Patrick ; Göbel, Heike ; Marmé, Dieter ; Beyersdorf, Friedhelm ; Lutter, Georg</creator><creatorcontrib>Heilmann, Claudia A U ; Attmann, Tim ; von Samson, Patrick ; Göbel, Heike ; Marmé, Dieter ; Beyersdorf, Friedhelm ; Lutter, Georg</creatorcontrib><description>Different therapy strategies for coronary disease in conventionally untreatable patients have been developed, among them transmyocardial laser revascularization (TMLR) and the application of growth factors. The objective of our study was to determine whether a combined therapy of TMLR with a vascular endothelial growth factor(121) (VEGF(121)) plasmid is able to stimulate the development of sufficient collateral circulation and hereby to preserve cardiac function. A severe stenosis of the left anterior descending artery was created in healthy pigs. After 1 week, perfusion and regional contractility were assessed at baseline. Afterwards, the ischemic area was treated with TMLR (n=8), intramyocardial injection of naked plasmid DNA encoding VEGF(121) (n=7), or both (n=7). Control animals were left untreated (n=8). After 3 months, the animals were re-examined and underwent immunohistological analysis. The number of capillaries increased only after injection of VEGF(121) plasmid alone compared to untreated ischemia and to the other therapy groups, whereas the number of arterioles was higher following TMLR treatment alone or in combination with VEGF(121) than it was in the case in untreated ischemic animals. However, only combined VEGF(121)+TLMR therapy resulted in an improvement in regional myocardial blood flow in comparison with 1 week ischemia, indicating the efficient development of collateral circulation. In contrast, better regional contractility compared to the 1-week baseline, as well as restoration of the pre-ischemic values, were achieved by both VEGF(121) and combined VEGF(121)+TLMR therapies. This study of chronic myocardial ischemia with a porcine model indicates a synergistic action of TMLR and VEGF(121) gene therapy. Combined treatment alone achieved an increase of regional myocardial perfusion, which accompanied arteriogenesis and corresponded with the restoration of regional function.</description><identifier>ISSN: 1010-7940</identifier><identifier>PMID: 12493508</identifier><language>eng</language><publisher>Germany</publisher><subject>Animals ; Chronic Disease ; Collateral Circulation ; Combined Modality Therapy ; DNA - administration &amp; dosage ; Endothelial Growth Factors - administration &amp; dosage ; Endothelial Growth Factors - genetics ; Genetic Therapy - methods ; Injections ; Intercellular Signaling Peptides and Proteins - administration &amp; dosage ; Intercellular Signaling Peptides and Proteins - genetics ; Laser Therapy - methods ; Lymphokines - administration &amp; dosage ; Lymphokines - genetics ; Myocardial Ischemia - surgery ; Myocardial Ischemia - therapy ; Myocardial Revascularization - methods ; Neovascularization, Physiologic ; Swine ; Transfection - methods ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors</subject><ispartof>European journal of cardio-thoracic surgery, 2003-01, Vol.23 (1), p.74-80</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12493508$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Heilmann, Claudia A U</creatorcontrib><creatorcontrib>Attmann, Tim</creatorcontrib><creatorcontrib>von Samson, Patrick</creatorcontrib><creatorcontrib>Göbel, Heike</creatorcontrib><creatorcontrib>Marmé, Dieter</creatorcontrib><creatorcontrib>Beyersdorf, Friedhelm</creatorcontrib><creatorcontrib>Lutter, Georg</creatorcontrib><title>Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?</title><title>European journal of cardio-thoracic surgery</title><addtitle>Eur J Cardiothorac Surg</addtitle><description>Different therapy strategies for coronary disease in conventionally untreatable patients have been developed, among them transmyocardial laser revascularization (TMLR) and the application of growth factors. The objective of our study was to determine whether a combined therapy of TMLR with a vascular endothelial growth factor(121) (VEGF(121)) plasmid is able to stimulate the development of sufficient collateral circulation and hereby to preserve cardiac function. A severe stenosis of the left anterior descending artery was created in healthy pigs. After 1 week, perfusion and regional contractility were assessed at baseline. Afterwards, the ischemic area was treated with TMLR (n=8), intramyocardial injection of naked plasmid DNA encoding VEGF(121) (n=7), or both (n=7). Control animals were left untreated (n=8). After 3 months, the animals were re-examined and underwent immunohistological analysis. The number of capillaries increased only after injection of VEGF(121) plasmid alone compared to untreated ischemia and to the other therapy groups, whereas the number of arterioles was higher following TMLR treatment alone or in combination with VEGF(121) than it was in the case in untreated ischemic animals. However, only combined VEGF(121)+TLMR therapy resulted in an improvement in regional myocardial blood flow in comparison with 1 week ischemia, indicating the efficient development of collateral circulation. In contrast, better regional contractility compared to the 1-week baseline, as well as restoration of the pre-ischemic values, were achieved by both VEGF(121) and combined VEGF(121)+TLMR therapies. This study of chronic myocardial ischemia with a porcine model indicates a synergistic action of TMLR and VEGF(121) gene therapy. Combined treatment alone achieved an increase of regional myocardial perfusion, which accompanied arteriogenesis and corresponded with the restoration of regional function.</description><subject>Animals</subject><subject>Chronic Disease</subject><subject>Collateral Circulation</subject><subject>Combined Modality Therapy</subject><subject>DNA - administration &amp; dosage</subject><subject>Endothelial Growth Factors - administration &amp; dosage</subject><subject>Endothelial Growth Factors - genetics</subject><subject>Genetic Therapy - methods</subject><subject>Injections</subject><subject>Intercellular Signaling Peptides and Proteins - administration &amp; dosage</subject><subject>Intercellular Signaling Peptides and Proteins - genetics</subject><subject>Laser Therapy - methods</subject><subject>Lymphokines - administration &amp; dosage</subject><subject>Lymphokines - genetics</subject><subject>Myocardial Ischemia - surgery</subject><subject>Myocardial Ischemia - therapy</subject><subject>Myocardial Revascularization - methods</subject><subject>Neovascularization, Physiologic</subject><subject>Swine</subject><subject>Transfection - methods</subject><subject>Vascular Endothelial Growth Factor A</subject><subject>Vascular Endothelial Growth Factors</subject><issn>1010-7940</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkM9Kw0AQxnNQbK2-guxJ9BDY3fzbnERKrULBg8VrmOxOmpVNNu4mlvhYPqEptuBpBr7fzHzfnAVzRhkNszyms-DS-w9KaRrx7CKYMR7nUULFPPjZOmh9M1oJTmkwxIBHRxx-gZeDAae_ode2JdI2pW5Rkb3ua3JSCbbK9jWaw-jO2f2kVSB76wjjjNy9r9ZPU3NPdtgimUAH3UiqSZa1s62W5N9p7WWNjYYwVPbAEqwqlL2f3IAxIwGlyNA9XAXnFRiP18e6CN6eVtvlc7h5Xb8sHzdhl8QiZCmHmLGSH0JHSYVpmgsWsZzHoEQCleJxVoLIcgEJTSRjESBKnicgoRLRIrj929o5-zmg74tm8ofGQIt28EXGhUhElE7gzREcygZV0TndgBuL04-jX3Ytebo</recordid><startdate>200301</startdate><enddate>200301</enddate><creator>Heilmann, Claudia A U</creator><creator>Attmann, Tim</creator><creator>von Samson, Patrick</creator><creator>Göbel, Heike</creator><creator>Marmé, Dieter</creator><creator>Beyersdorf, Friedhelm</creator><creator>Lutter, Georg</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200301</creationdate><title>Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?</title><author>Heilmann, Claudia A U ; Attmann, Tim ; von Samson, Patrick ; Göbel, Heike ; Marmé, Dieter ; Beyersdorf, Friedhelm ; Lutter, Georg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p548-162a411b2006335fe6698131924ad85afd247ba8798a505c113aeec295acaf83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Chronic Disease</topic><topic>Collateral Circulation</topic><topic>Combined Modality Therapy</topic><topic>DNA - administration &amp; dosage</topic><topic>Endothelial Growth Factors - administration &amp; dosage</topic><topic>Endothelial Growth Factors - genetics</topic><topic>Genetic Therapy - methods</topic><topic>Injections</topic><topic>Intercellular Signaling Peptides and Proteins - administration &amp; dosage</topic><topic>Intercellular Signaling Peptides and Proteins - genetics</topic><topic>Laser Therapy - methods</topic><topic>Lymphokines - administration &amp; dosage</topic><topic>Lymphokines - genetics</topic><topic>Myocardial Ischemia - surgery</topic><topic>Myocardial Ischemia - therapy</topic><topic>Myocardial Revascularization - methods</topic><topic>Neovascularization, Physiologic</topic><topic>Swine</topic><topic>Transfection - methods</topic><topic>Vascular Endothelial Growth Factor A</topic><topic>Vascular Endothelial Growth Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heilmann, Claudia A U</creatorcontrib><creatorcontrib>Attmann, Tim</creatorcontrib><creatorcontrib>von Samson, Patrick</creatorcontrib><creatorcontrib>Göbel, Heike</creatorcontrib><creatorcontrib>Marmé, Dieter</creatorcontrib><creatorcontrib>Beyersdorf, Friedhelm</creatorcontrib><creatorcontrib>Lutter, Georg</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cardio-thoracic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heilmann, Claudia A U</au><au>Attmann, Tim</au><au>von Samson, Patrick</au><au>Göbel, Heike</au><au>Marmé, Dieter</au><au>Beyersdorf, Friedhelm</au><au>Lutter, Georg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?</atitle><jtitle>European journal of cardio-thoracic surgery</jtitle><addtitle>Eur J Cardiothorac Surg</addtitle><date>2003-01</date><risdate>2003</risdate><volume>23</volume><issue>1</issue><spage>74</spage><epage>80</epage><pages>74-80</pages><issn>1010-7940</issn><abstract>Different therapy strategies for coronary disease in conventionally untreatable patients have been developed, among them transmyocardial laser revascularization (TMLR) and the application of growth factors. The objective of our study was to determine whether a combined therapy of TMLR with a vascular endothelial growth factor(121) (VEGF(121)) plasmid is able to stimulate the development of sufficient collateral circulation and hereby to preserve cardiac function. A severe stenosis of the left anterior descending artery was created in healthy pigs. After 1 week, perfusion and regional contractility were assessed at baseline. Afterwards, the ischemic area was treated with TMLR (n=8), intramyocardial injection of naked plasmid DNA encoding VEGF(121) (n=7), or both (n=7). Control animals were left untreated (n=8). After 3 months, the animals were re-examined and underwent immunohistological analysis. The number of capillaries increased only after injection of VEGF(121) plasmid alone compared to untreated ischemia and to the other therapy groups, whereas the number of arterioles was higher following TMLR treatment alone or in combination with VEGF(121) than it was in the case in untreated ischemic animals. However, only combined VEGF(121)+TLMR therapy resulted in an improvement in regional myocardial blood flow in comparison with 1 week ischemia, indicating the efficient development of collateral circulation. In contrast, better regional contractility compared to the 1-week baseline, as well as restoration of the pre-ischemic values, were achieved by both VEGF(121) and combined VEGF(121)+TLMR therapies. This study of chronic myocardial ischemia with a porcine model indicates a synergistic action of TMLR and VEGF(121) gene therapy. Combined treatment alone achieved an increase of regional myocardial perfusion, which accompanied arteriogenesis and corresponded with the restoration of regional function.</abstract><cop>Germany</cop><pmid>12493508</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1010-7940
ispartof European journal of cardio-thoracic surgery, 2003-01, Vol.23 (1), p.74-80
issn 1010-7940
language eng
recordid cdi_proquest_miscellaneous_72885836
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current)
subjects Animals
Chronic Disease
Collateral Circulation
Combined Modality Therapy
DNA - administration & dosage
Endothelial Growth Factors - administration & dosage
Endothelial Growth Factors - genetics
Genetic Therapy - methods
Injections
Intercellular Signaling Peptides and Proteins - administration & dosage
Intercellular Signaling Peptides and Proteins - genetics
Laser Therapy - methods
Lymphokines - administration & dosage
Lymphokines - genetics
Myocardial Ischemia - surgery
Myocardial Ischemia - therapy
Myocardial Revascularization - methods
Neovascularization, Physiologic
Swine
Transfection - methods
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
title Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T11%3A23%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transmyocardial%20laser%20revascularization%20combined%20with%20vascular%20endothelial%20growth%20factor%20121%20(VEGF121)%20gene%20therapy%20for%20chronic%20myocardial%20ischemia--do%20the%20effects%20really%20add%20up?&rft.jtitle=European%20journal%20of%20cardio-thoracic%20surgery&rft.au=Heilmann,%20Claudia%20A%20U&rft.date=2003-01&rft.volume=23&rft.issue=1&rft.spage=74&rft.epage=80&rft.pages=74-80&rft.issn=1010-7940&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E72885836%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72885836&rft_id=info:pmid/12493508&rfr_iscdi=true